Fundraising FoxHinge Bio
Burlingame, US · Founded 2015 · Delaware corporation · 5 known investors
Find your way into Hinge Bio
Sign up to see every warm intro you have to Hinge Bio
- Paths you didn't know you had: your email and LinkedIn already hold routes to the Hinge Bio team. We find them for you
- 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
- Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone
Days of research, done the moment you sign in, with every route ranked by how warm it is.
Hinge Bio is a biotechnology company developing next-generation therapeutics based on its GEM-DIMER platform, aimed at improving efficacy and reducing resistance and side effects. Its focus areas include autoimmune and inflammatory diseases, cancer, and other conditions.
Founders & leadership
Hinge Bio was founded in 2015 by Daniel J. Capon and Carin Mueller Rollins.
DJ
Daniel J. CaponCo-founder
CM
Carin Mueller RollinsCo-Founder & Chief Operating Officer
HE
Harold E. Selick, PhDExecutive
HE
Harold E. "Barry" SelickChief Executive Officer & Director
PB
Paul BrunettaChief Medical OfficerPaul Brunetta is Chief Medical Officer of Hinge Bio, a biotechnology company developing therapeutics based on its GEM-DIMER platform. He is a physician and clinical researcher with over 22 years of biotechnology industry experience, and maintains a volunteer public health focus on smoking cessation outcomes.
JC
Joshua CarleChief Business Officer
KQ
Kristen QuigleyChief Clinical Operations OfficerKristen Quigley brings 30 years of clinical research experience across phase I-IV trials, with leadership roles at biotech companies and contract research organizations (CROs). Her disease expertise spans oncology, autoimmune, renal, gastrointestinal, and arthritis indications, and she has managed multiple clinical vendor relationships over her career.
AN
Alpana NareshChief Manufacturing OfficerShe brings over 20 years of biotechnology experience, with a decade of strategic, operational, and regulatory work in biopharmaceutical product development across early and late-stage programs, including expertise in immunoglobulins, monoclonal antibodies, and multispecific antibody formats.
WD
William D. UngerNamed on SEC filing
SS
Samuel SaksNamed on SEC filing
Investors · 5
Point72✓ confirmed by Hinge BioStamford
How we know: the company's own site · funding news · Not right? Tell us
Agent Capitallisted by Agent CapitalWaltham
How we know: Agent Capital's portfolio page · the VCSheet dataset · Not right? Tell us
Baruch Future Ventureslisted by Baruch Future VenturesSan Francisco · $100K – $1M
How we know: the VCSheet dataset · Not right? Tell us
InVivium Capitallisted by InVivium CapitalChicago
How we know: InVivium Capital's portfolio page · Not right? Tell us
Ridgeback CapitalreportedNew York
How we know: funding news · Not right? Tell us
Reported raises · per SEC filings
Form D private placements$66.8M disclosed across 3 rounds · 2020–2024
▶$30.6MraisedJan 2025 · 82 investors · BiotechnologyRule 506(b)
▶$30.6MraisedJan 2025 · 82 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- John Misha PetkevichDirector
- Alex SilversteinDirector
- Malcolm GefterDirector
- Jeffrey Long-McGieDirector
- Harold E. Selick, PhDExecutive Officer, Director
- Miriam SiekevitzExecutive Officer
- Offering amount
- $40.8M
- Amount sold
- $30.6M
- First sale
- Dec 2024
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$18MraisedFeb 2021 · 77 investors · BiotechnologyRule 506(b)
▶$18MraisedFeb 2021 · 77 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Malcolm GefterDirector
- Miriam SiekevitzExecutive Officer
- William UngerDirector
- John Misha PetkevichDirector
- Daniel CaponExecutive Officer, Director
- Carin RollinsExecutive Officer, Director
- Offering amount
- $18M
- Amount sold
- $18M
- Finders' fees
- $2.1M
- Placement agents
- Arcadia Securities, LLC
- First sale
- Dec 2020
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$18.2MraisedApr 2020 · 100 investors · BiotechnologyRule 506(b)
▶$18.2MraisedApr 2020 · 100 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Daniel J. CaponDirector
- Miriam SiekevitzExecutive Officer
- Malcolm L. GefterDirector
- William D. UngerDirector
- Samuel SaksDirector
- Carin M. RollinsExecutive Officer, Director
- J. Misha PetkevichDirector
- Offering amount
- $19M
- Amount sold
- $18.2M
- Minimum investment
- $1
- Sales commissions
- $833.8K
- Placement agents
- Arcadia Securities, LLC
- First sale
- Feb 2020
- Incorporated
- Corporation, Delaware, 2015
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Related companies · 2
BridgebioBridgeBio develops treatments for genetic conditions and cancers using a decentralized hub-and-spoke model, where autonomous teams focus on specific diseases or drug candidates while a central hub provides clinical, regulatory, and commercial support. The company partners with academic institutions to advance early-stage research toward late-stage clinical trials.
BioworldBioWorld is a suite of daily news and data services covering therapeutics, medical technology, biopharma business transactions, and drug R&D, serving biopharmaceutical and medtech industry professionals. Owned by Clarivate, it publishes products including BioWorld, BioWorld Science, and BioWorld Asia with reporting from writers stationed globally.
Companies working in the same space as Hinge Bio.
Non-dilutive funding · 2 SBIR/STTR awards
Federal grants — no equity taken| Agency | Phase | Year | Amount |
|---|---|---|---|
| National Science Foundation | Phase I | 2018 | $224.5K |
| National Institutes of Health (NIH)National Institutes of Health | Phase I | 2017 | $224.7K |
Source: SBIR.gov award data (U.S. Small Business Administration). SBIR/STTR awards are competitive federal R&D grants and contracts — non-dilutive capital alongside any venture rounds above.
In the news
Frequently asked questions
- What does Hinge Bio do?
- Hinge Bio is a biotechnology company developing next-generation therapeutics based on its GEM-DIMER platform, aimed at improving efficacy and reducing resistance and side effects. Its focus areas include autoimmune and inflammatory diseases, cancer, and other conditions.
- Who founded Hinge Bio?
- Hinge Bio was founded by Daniel J. Capon, Carin Mueller Rollins in 2015.
- Who are Hinge Bio's investors?
- Hinge Bio's investors include Point72, Agent Capital, Baruch Future Ventures, InVivium Capital, Ridgeback Capital.
- How much funding has Hinge Bio raised?
- Hinge Bio has disclosed $66.8M raised across 3 rounds.
- Where is Hinge Bio headquartered?
- Hinge Bio is headquartered in Burlingame, US.